Dare Bioscience GAAP EPS of -$0.18 misses by $0.02
Dare Bioscience reported Q3 GAAP EPS of -$0.18, missing estimates by $0.02. Revenue rose to $48,000 from $2,300 year-over-year, according to the company.
How this was made
The 30-second read
Why it matters
A GAAP EPS miss typically pressures near-term sentiment and can affect how traders price future burn rate and milestone-driven value, especially for smaller biotech issuers.
Market read
Traders get a fresh earnings datapoint (GAAP EPS miss) plus a reported revenue figure, which can drive immediate repricing of expectations.
What to watch
The excerpt lacks guidance, cash balance, and pipeline/clinical catalysts; those could offset the GAAP miss if management framed a clear path to profitability.
Background
The piece summarizes Daré Bioscience’s Q3 results from a press release, focusing on GAAP EPS and total revenue for the quarter ended September 30, 2026.
Ticker impact
Daré Bioscience reported Q3 GAAP EPS of -$0.18, missing by $0.02, alongside sharply higher reported revenue versus the prior year period.
Likely pressure as traders reprice profitability expectations after the GAAP EPS miss.
The article provides the company’s own Q3 GAAP EPS miss and revenue figures, which are direct inputs to earnings expectations and valuation for a small-cap biotech.
Market effects
Reinforces risk-off sentiment for pre-commercial or loss-making biotech names when GAAP profitability misses.
Limited, company-specific impact likely confined to US small-cap biotech sentiment.
Low, no cross-market policy or macro linkage indicated.
Counterpoint
The revenue comparison appears distorted by a very low prior-year quarter, so the EPS miss may matter more than the headline revenue swing for forward expectations.
Key entities
- companyDaré Bioscience, Inc.
Reported Q3 GAAP EPS of -$0.18 (miss) and total revenue of about $48,000 for the quarter ended September 30, 2026.
